Tags

Type your tag names separated by a space and hit enter

Etiology and current management of cancer-related hypercalcemia.
Oncology (Williston Park). 1992 Oct; 6(10):37-43; discussion 43, 47-50.O

Abstract

Important new information has been gained concerning the etiology of cancer-related hypercalcemia and thus treatment recommendations are changing. The most common cause of hypercalcemia in cancer patients is the parathyroid hormone-like peptide, PTH-RP. Patients with elevated serum calcium due to elaboration of parathyroid hormone-like peptide commonly present with hypophosphatemia and a relatively resistant form of hypercalcemia. Our new knowledge has led to recommendations against massive amounts of IV fluids and large doses of diuretics, which restore normocalcemia in only a minority of patients. New potent drugs such as pamidronate and gallium nitrate directly inhibit accelerated bone resorption. Thus, consideration should be given to the early administration of antiresorptive drugs immediately after intravascular volume has been repleted and urinary output has been established.

Authors+Show Affiliations

Warrell RP
Memorial Sloan-Kettering Cancer Center, New York, New York.

MeSH

HumansHypercalcemiaNeoplasm ProteinsNeoplasmsParathyroid HormoneParathyroid Hormone-Related ProteinProteins

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

1390013

Citation

Warrell, R P.. "Etiology and Current Management of Cancer-related Hypercalcemia." Oncology (Williston Park, N.Y.), vol. 6, no. 10, 1992, pp. 37-43; discussion 43, 47-50.
Warrell RP. Etiology and current management of cancer-related hypercalcemia. Oncology (Williston Park). 1992;6(10):37-43; discussion 43, 47-50.
Warrell, R. P. (1992). Etiology and current management of cancer-related hypercalcemia. Oncology (Williston Park, N.Y.), 6(10), 37-43; discussion 43, 47-50.
Warrell RP. Etiology and Current Management of Cancer-related Hypercalcemia. Oncology (Williston Park). 1992;6(10):37-43; discussion 43, 47-50. PubMed PMID: 1390013.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Etiology and current management of cancer-related hypercalcemia. A1 - Warrell,R P,Jr PY - 1992/10/11/pubmed PY - 2001/3/28/medline PY - 1992/10/11/entrez SP - 37-43; discussion 43, 47-50 JF - Oncology (Williston Park, N.Y.) JO - Oncology (Williston Park) VL - 6 IS - 10 N2 - Important new information has been gained concerning the etiology of cancer-related hypercalcemia and thus treatment recommendations are changing. The most common cause of hypercalcemia in cancer patients is the parathyroid hormone-like peptide, PTH-RP. Patients with elevated serum calcium due to elaboration of parathyroid hormone-like peptide commonly present with hypophosphatemia and a relatively resistant form of hypercalcemia. Our new knowledge has led to recommendations against massive amounts of IV fluids and large doses of diuretics, which restore normocalcemia in only a minority of patients. New potent drugs such as pamidronate and gallium nitrate directly inhibit accelerated bone resorption. Thus, consideration should be given to the early administration of antiresorptive drugs immediately after intravascular volume has been repleted and urinary output has been established. SN - 0890-9091 UR - https://www.unboundmedicine.com/medline/citation/1390013/Etiology_and_current_management_of_cancer_related_hypercalcemia_ DB - PRIME DP - Unbound Medicine ER -